Skip to main content
PMC home page
Journal of Psychiatry & Neuroscience : JPN logoLink to Journal of Psychiatry & Neuroscience : JPN
. 2000 Nov;25(5):497–508.

Psychopharmacotherapy of anorexia nervosa, bulimia nervosa and binge-eating disorder

S Kruger 1, SH Kennedy 1
PMCID: PMC1408011  PMID: 11109300

Abstract

Pharmacotherapy for anorexia nervosa is considered to be of limited efficacy. However, many studies suffer methodological limitations, and the utility of newer drugs in the treatment of anorexia has not been examined yet. Although there have been more fruitful investigations on the efficacy of medication in the management of bulimia nervosa, there are still many unresolved issues regarding the optimal management of partial remission during the acute treatment phase and the intensity and duration of pharmacotherapy to achieve optimal prophylaxis. Selective serotonin reuptake inhibitors (SSRIs) control the binge urges in binge-eating disorder, but more trials are required to investigate the utility of SSRIs and other agents in maintenance treatment. We review the current status of psychopharmacotherapy for anorexia nervosa, bulimia nervosa and binge-eating disorder and evaluate the merits of newer agents in the treatment of these disorders.

Full text

PDF
500

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Advokat C., Kutlesic V. Pharmacotherapy of the eating disorders: a commentary. Neurosci Biobehav Rev. 1995 Spring;19(1):59–66. doi: 10.1016/0149-7634(94)00044-2. [DOI] [PubMed] [Google Scholar]
  2. Agras W. S. Pharmacotherapy of bulimia nervosa and binge eating disorder: longer-term outcomes. Psychopharmacol Bull. 1997;33(3):433–436. [PubMed] [Google Scholar]
  3. Agras W. S., Rossiter E. M., Arnow B., Schneider J. A., Telch C. F., Raeburn S. D., Bruce B., Perl M., Koran L. M. Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: a controlled comparison. Am J Psychiatry. 1992 Jan;149(1):82–87. doi: 10.1176/ajp.149.1.82. [DOI] [PubMed] [Google Scholar]
  4. Agras W. S., Rossiter E. M., Arnow B., Telch C. F., Raeburn S. D., Bruce B., Koran L. M. One-year follow-up of psychosocial and pharmacologic treatments for bulimia nervosa. J Clin Psychiatry. 1994 May;55(5):179–183. [PubMed] [Google Scholar]
  5. Alger S. A., Schwalberg M. D., Bigaouette J. M., Michalek A. V., Howard L. J. Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects. Am J Clin Nutr. 1991 Apr;53(4):865–871. doi: 10.1093/ajcn/53.4.865. [DOI] [PubMed] [Google Scholar]
  6. Anderson I. M., Parry-Billings M., Newsholme E. A., Fairburn C. G., Cowen P. J. Dieting reduces plasma tryptophan and alters brain 5-HT function in women. Psychol Med. 1990 Nov;20(4):785–791. doi: 10.1017/s0033291700036473. [DOI] [PubMed] [Google Scholar]
  7. Attia E., Haiman C., Walsh B. T., Flater S. R. Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am J Psychiatry. 1998 Apr;155(4):548–551. doi: 10.1176/ajp.155.4.548. [DOI] [PubMed] [Google Scholar]
  8. Ayuso-Gutierrez J. L., Palazón M., Ayuso-Mateos J. L. Open trial of fluvoxamine in the treatment of bulimia nervosa. Int J Eat Disord. 1994 Apr;15(3):245–249. doi: 10.1002/1098-108x(199404)15:3<245::aid-eat2260150307>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  9. Baptista T., Teneud L., Contreras Q., Alastre T., Burguera J. L., de Burguera M., de Baptista E., Weiss S., Hernàndez L. Lithium and body weight gain. Pharmacopsychiatry. 1995 Mar;28(2):35–44. doi: 10.1055/s-2007-979586. [DOI] [PubMed] [Google Scholar]
  10. Barcai Lithium in adult anorexia nervosa. A pilot report on two patients. Acta Psychiatr Scand. 1977 Feb;55(2):97–101. doi: 10.1111/j.1600-0447.1977.tb00144.x. [DOI] [PubMed] [Google Scholar]
  11. Barry V. C., Klawans H. L. On the role of dopamine in the pathophysiology of anorexia nervosa. J Neural Transm. 1976;38(2):107–122. doi: 10.1007/BF01262969. [DOI] [PubMed] [Google Scholar]
  12. Bastiani A. M., Altemus M., Pigott T. A., Rubenstein C., Weltzin T. E., Kaye W. H. Comparison of obsessions and compulsions in patients with anorexia nervosa and obsessive compulsive disorder. Biol Psychiatry. 1996 Jun 1;39(11):966–969. doi: 10.1016/0006-3223(95)00306-1. [DOI] [PubMed] [Google Scholar]
  13. Bergh C., Eriksson M., Lindberg G., Södersten P. Selective serotonin reuptake inhibitors in anorexia. Lancet. 1996 Nov 23;348(9039):1459–1460. doi: 10.1016/S0140-6736(04)70113-0. [DOI] [PubMed] [Google Scholar]
  14. Beumont P. J., Russell J. D., Touyz S. W., Buckley C., Lowinger K., Talbot P., Johnson G. F. Intensive nutritional counselling in bulimia nervosa: a role for supplementation with fluoxetine? Aust N Z J Psychiatry. 1997 Aug;31(4):514–524. doi: 10.3109/00048679709065073. [DOI] [PubMed] [Google Scholar]
  15. Biederman J., Herzog D. B., Rivinus T. M., Harper G. P., Ferber R. A., Rosenbaum J. F., Harmatz J. S., Tondorf R., Orsulak P. J., Schildkraut J. J. Amitriptyline in the treatment of anorexia nervosa: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 1985 Feb;5(1):10–16. [PubMed] [Google Scholar]
  16. Blouin J., Blouin A., Perez E., Barlow J. Bulimia: independence of antibulimic and antidepressant properties of desipramine. Can J Psychiatry. 1989 Feb;34(1):24–29. doi: 10.1177/070674378903400107. [DOI] [PubMed] [Google Scholar]
  17. Broocks A., Liu J., Pirke K. M. Semistarvation-induced hyperactivity compensates for decreased norepinephrine and dopamine turnover in the mediobasal hypothalamus of the rat. J Neural Transm Gen Sect. 1990;79(1-2):113–124. doi: 10.1007/BF01251006. [DOI] [PubMed] [Google Scholar]
  18. Bulik C. M., Sullivan P. F., Carter F. A., Joyce P. R. Lifetime anxiety disorders in women with bulimia nervosa. Compr Psychiatry. 1996 Sep-Oct;37(5):368–374. doi: 10.1016/s0010-440x(96)90019-x. [DOI] [PubMed] [Google Scholar]
  19. Crisp A. H., Lacey J. H., Crutchfield M. Clomipramine and 'drive' in people with anorexia nervosa: an in-patient study. Br J Psychiatry. 1987 Mar;150:355–358. doi: 10.1192/bjp.150.3.355. [DOI] [PubMed] [Google Scholar]
  20. Crisp A. H., Norton K., Gowers S., Halek C., Bowyer C., Yeldham D., Levett G., Bhat A. A controlled study of the effect of therapies aimed at adolescent and family psychopathology in anorexia nervosa. Br J Psychiatry. 1991 Sep;159:325–333. doi: 10.1192/bjp.159.3.325. [DOI] [PubMed] [Google Scholar]
  21. Demitrack M. A., Lesem M. D., Listwak S. J., Brandt H. A., Jimerson D. C., Gold P. W. CSF oxytocin in anorexia nervosa and bulimia nervosa: clinical and pathophysiologic considerations. Am J Psychiatry. 1990 Jul;147(7):882–886. doi: 10.1176/ajp.147.7.882. [DOI] [PubMed] [Google Scholar]
  22. Devlin M. J., Goldfein J. A., Carino J. S., Wolk S. L. Open treatment of overweight binge eaters with phentermine and fluoxetine as an adjunct to cognitive-behavioral therapy. Int J Eat Disord. 2000 Nov;28(3):325–332. doi: 10.1002/1098-108x(200011)28:3<325::aid-eat10>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  23. Dunner D. L., Zisook S., Billow A. A., Batey S. R., Johnston J. A., Ascher J. A. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry. 1998 Jul;59(7):366–373. doi: 10.4088/jcp.v59n0705. [DOI] [PubMed] [Google Scholar]
  24. Fallon B. A., Walsh B. T., Sadik C., Saoud J. B., Lukasik V. Outcome and clinical course in inpatient bulimic women: a 2- to 9-year follow-up study. J Clin Psychiatry. 1991 Jun;52(6):272–278. [PubMed] [Google Scholar]
  25. Ferguson C. P., La Via M. C., Crossan P. J., Kaye W. H. Are serotonin selective reuptake inhibitors effective in underweight anorexia nervosa? Int J Eat Disord. 1999 Jan;25(1):11–17. doi: 10.1002/(sici)1098-108x(199901)25:1<11::aid-eat2>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  26. Ferguson J. M., Feighner J. P. Fluoxetine-induced weight loss in overweight non-depressed humans. Int J Obes. 1987;11 (Suppl 3):163–170. [PubMed] [Google Scholar]
  27. Fernstrom J. D., Faller D. V. Neutral amino acids in the brain: changes in response to food ingestion. J Neurochem. 1978 Jun;30(6):1531–1538. doi: 10.1111/j.1471-4159.1978.tb10489.x. [DOI] [PubMed] [Google Scholar]
  28. Fichter M. M., Leibl K., Rief W., Brunner E., Schmidt-Auberger S., Engel R. R. Fluoxetine versus placebo: a double-blind study with bulimic inpatients undergoing intensive psychotherapy. Pharmacopsychiatry. 1991 Jan;24(1):1–7. doi: 10.1055/s-2007-1014424. [DOI] [PubMed] [Google Scholar]
  29. Fink G., Sumner B. E., Rosie R., Grace O., Quinn J. P. Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cell Mol Neurobiol. 1996 Jun;16(3):325–344. doi: 10.1007/BF02088099. [DOI] [PubMed] [Google Scholar]
  30. Finley P. R. Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Ann Pharmacother. 1994 Dec;28(12):1359–1369. doi: 10.1177/106002809402801207. [DOI] [PubMed] [Google Scholar]
  31. Freeman C. Drug treatment for bulimia nervosa. Neuropsychobiology. 1998;37(2):72–79. doi: 10.1159/000026481. [DOI] [PubMed] [Google Scholar]
  32. Gardiner H. M., Freeman C. P., Jesinger D. K., Collins S. A. Fluvoxamine: an open pilot study in moderately obese female patients suffering from atypical eating disorders and episodes of bingeing. Int J Obes Relat Metab Disord. 1993 May;17(5):301–305. [PubMed] [Google Scholar]
  33. Gatti E., Porrini M., Noè D., Crovetti R., Testolin G. Plasma amino acids changes in obese patients on very low-calorie diets. Int J Vitam Nutr Res. 1994;64(1):81–85. [PubMed] [Google Scholar]
  34. Geretsegger C., Greimel K. V., Roed I. S., Hesselink J. M. Ipsapirone in the treatment of bulimia nervosa: an open pilot study. Int J Eat Disord. 1995 May;17(4):359–363. doi: 10.1002/1098-108x(199505)17:4<359::aid-eat2260170407>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  35. Goldbloom D. S., Olmsted M. P. Pharmacotherapy of bulimia nervosa with fluoxetine: assessment of clinically significant attitudinal change. Am J Psychiatry. 1993 May;150(5):770–774. doi: 10.1176/ajp.150.5.770. [DOI] [PubMed] [Google Scholar]
  36. Goldbloom D. S., Olmsted M., Davis R., Clewes J., Heinmaa M., Rockert W., Shaw B. A randomized controlled trial of fluoxetine and cognitive behavioral therapy for bulimia nervosa: short-term outcome. Behav Res Ther. 1997 Sep;35(9):803–811. doi: 10.1016/s0005-7967(97)00041-7. [DOI] [PubMed] [Google Scholar]
  37. Goldstein D. J., Wilson M. G., Ascroft R. C., al-Banna M. Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression. Int J Eat Disord. 1999 Jan;25(1):19–27. doi: 10.1002/(sici)1098-108x(199901)25:1<19::aid-eat3>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  38. Goldstein D. J., Wilson M. G., Thompson V. L., Potvin J. H., Rampey A. H., Jr Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group. Br J Psychiatry. 1995 May;166(5):660–666. doi: 10.1192/bjp.166.5.660. [DOI] [PubMed] [Google Scholar]
  39. Gorman J. M., Kent J. M. SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. J Clin Psychiatry. 1999;60 (Suppl 4):33–39. [PubMed] [Google Scholar]
  40. Gross H. A., Ebert M. H., Faden V. B., Goldberg S. C., Nee L. E., Kaye W. H. A double-blind controlled trial of lithium carbonate primary anorexia nervosa. J Clin Psychopharmacol. 1981 Nov;1(6):376–381. doi: 10.1097/00004714-198111000-00005. [DOI] [PubMed] [Google Scholar]
  41. Gross H. A., Lake C. R., Ebert M. H., Ziegler M. G., Kopin I. J. Catecholamine metabolism in primary anorexia nervosa. J Clin Endocrinol Metab. 1979 Dec;49(6):805–809. doi: 10.1210/jcem-49-6-805. [DOI] [PubMed] [Google Scholar]
  42. Gwirtsman H. E., Guze B. H., Yager J., Gainsley B. Fluoxetine treatment of anorexia nervosa: an open clinical trial. J Clin Psychiatry. 1990 Sep;51(9):378–382. [PubMed] [Google Scholar]
  43. Hadigan C. M., Walsh B. T., Buttinger C., Hollander E. Behavioral and neuroendocrine responses to metaCPP in anorexia nervosa. Biol Psychiatry. 1995 Apr 15;37(8):504–511. doi: 10.1016/0006-3223(94)00169-4. [DOI] [PubMed] [Google Scholar]
  44. Haleem D. J., Haider S. Food restriction decreases serotonin and its synthesis rate in the hypothalamus. Neuroreport. 1996 Apr 26;7(6):1153–1156. doi: 10.1097/00001756-199604260-00011. [DOI] [PubMed] [Google Scholar]
  45. Halmi K. A., Eckert E., LaDu T. J., Cohen J. Anorexia nervosa. Treatment efficacy of cyproheptadine and amitriptyline. Arch Gen Psychiatry. 1986 Feb;43(2):177–181. doi: 10.1001/archpsyc.1986.01800020087011. [DOI] [PubMed] [Google Scholar]
  46. Hatsukami D. K., Mitchell J. E., Eckert E. D. Eating disorders: a variant of mood disorders? Psychiatr Clin North Am. 1984 Jun;7(2):349–365. [PubMed] [Google Scholar]
  47. Herridge P. L., Pope H. G., Jr Treatment of bulimia and rapid-cycling bipolar disorder with sodium valproate: a case report. J Clin Psychopharmacol. 1985 Aug;5(4):229–230. [PubMed] [Google Scholar]
  48. Holderness C. C., Brooks-Gunn J., Warren M. P. Co-morbidity of eating disorders and substance abuse review of the literature. Int J Eat Disord. 1994 Jul;16(1):1–34. doi: 10.1002/1098-108x(199407)16:1<1::aid-eat2260160102>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  49. Horne R. L., Ferguson J. M., Pope H. G., Jr, Hudson J. I., Lineberry C. G., Ascher J., Cato A. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry. 1988 Jul;49(7):262–266. [PubMed] [Google Scholar]
  50. Hsu L. K., Clement L., Santhouse R., Ju E. S. Treatment of bulimia nervosa with lithium carbonate. A controlled study. J Nerv Ment Dis. 1991 Jun;179(6):351–355. doi: 10.1097/00005053-199106000-00008. [DOI] [PubMed] [Google Scholar]
  51. Hudson J. I., McElroy S. L., Raymond N. C., Crow S., Keck P. E., Jr, Carter W. P., Mitchell J. E., Strakowski S. M., Pope H. G., Jr, Coleman B. S. Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. Am J Psychiatry. 1998 Dec;155(12):1756–1762. doi: 10.1176/ajp.155.12.1756. [DOI] [PubMed] [Google Scholar]
  52. Huether G., Zhou D., Schmidt S., Wiltfang J., Rüther E. Long-term food restriction down-regulates the density of serotonin transporters in the rat frontal cortex. Biol Psychiatry. 1997 Jun 15;41(12):1174–1180. doi: 10.1016/s0006-3223(96)00265-x. [DOI] [PubMed] [Google Scholar]
  53. Hughes P. L., Wells L. A., Cunningham C. J., Ilstrup D. M. Treating bulimia with desipramine. A double-blind, placebo-controlled study. Arch Gen Psychiatry. 1986 Feb;43(2):182–186. doi: 10.1001/archpsyc.1986.01800020092012. [DOI] [PubMed] [Google Scholar]
  54. Jimerson D. C., Lesem M. D., Kaye W. H., Brewerton T. D. Low serotonin and dopamine metabolite concentrations in cerebrospinal fluid from bulimic patients with frequent binge episodes. Arch Gen Psychiatry. 1992 Feb;49(2):132–138. doi: 10.1001/archpsyc.1992.01820020052007. [DOI] [PubMed] [Google Scholar]
  55. Kaplan A. S., Garfinkel P. E., Darby P. L., Garner D. M. Carbamazepine in the treatment of bulimia. Am J Psychiatry. 1983 Sep;140(9):1225–1226. doi: 10.1176/ajp.140.9.1225. [DOI] [PubMed] [Google Scholar]
  56. Kaye W. H., Ballenger J. C., Lydiard R. B., Stuart G. W., Laraia M. T., O'Neil P., Fossey M. D., Stevens V., Lesser S., Hsu G. CSF monoamine levels in normal-weight bulimia: evidence for abnormal noradrenergic activity. Am J Psychiatry. 1990 Feb;147(2):225–229. doi: 10.1176/ajp.147.2.225. [DOI] [PubMed] [Google Scholar]
  57. Kaye W. H., Ebert M. H., Gwirtsman H. E., Weiss S. R. Differences in brain serotonergic metabolism between nonbulimic and bulimic patients with anorexia nervosa. Am J Psychiatry. 1984 Dec;141(12):1598–1601. doi: 10.1176/ajp.141.12.1598. [DOI] [PubMed] [Google Scholar]
  58. Kaye W. H., Gwirtsman H. E., Brewerton T. D., George D. T., Wurtman R. J. Bingeing behavior and plasma amino acids: a possible involvement of brain serotonin in bulimia nervosa. Psychiatry Res. 1988 Jan;23(1):31–43. doi: 10.1016/0165-1781(88)90032-7. [DOI] [PubMed] [Google Scholar]
  59. Kaye W. H., Gwirtsman H. E., George D. T., Ebert M. H. Altered serotonin activity in anorexia nervosa after long-term weight restoration. Does elevated cerebrospinal fluid 5-hydroxyindoleacetic acid level correlate with rigid and obsessive behavior? Arch Gen Psychiatry. 1991 Jun;48(6):556–562. doi: 10.1001/archpsyc.1991.01810300068010. [DOI] [PubMed] [Google Scholar]
  60. Kaye W. H., Gwirtsman H. E., George D. T., Jimerson D. C., Ebert M. H. CSF 5-HIAA concentrations in anorexia nervosa: reduced values in underweight subjects normalize after weight gain. Biol Psychiatry. 1988 Jan 1;23(1):102–105. doi: 10.1016/0006-3223(88)90113-8. [DOI] [PubMed] [Google Scholar]
  61. Kaye W. H., Weltzin T. E., Hsu L. K., Bulik C. M. An open trial of fluoxetine in patients with anorexia nervosa. J Clin Psychiatry. 1991 Nov;52(11):464–471. [PubMed] [Google Scholar]
  62. Kaye W., Gendall K., Strober M. Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa. Biol Psychiatry. 1998 Nov 1;44(9):825–838. doi: 10.1016/s0006-3223(98)00195-4. [DOI] [PubMed] [Google Scholar]
  63. Kaye W., Strober M., Stein D., Gendall K. New directions in treatment research of anorexia and bulimia nervosa. Biol Psychiatry. 1999 May 15;45(10):1285–1292. doi: 10.1016/s0006-3223(99)00048-7. [DOI] [PubMed] [Google Scholar]
  64. Kennedy S. H., Goldbloom D. S. Current perspectives on drug therapies for anorexia nervosa and bulimia nervosa. Drugs. 1991 Mar;41(3):367–377. doi: 10.2165/00003495-199141030-00005. [DOI] [PubMed] [Google Scholar]
  65. Kennedy S. H., Goldbloom D. S., Ralevski E., Davis C., D'Souza J. D., Lofchy J. Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of brofaromine. J Clin Psychopharmacol. 1993 Dec;13(6):415–422. [PubMed] [Google Scholar]
  66. Kennedy S. H., Piran N., Garfinkel P. E. Monoamine oxidase inhibitor therapy for anorexia nervosa and bulimia: a preliminary trial of isocarboxazid. J Clin Psychopharmacol. 1985 Oct;5(5):279–285. doi: 10.1097/00004714-198510000-00005. [DOI] [PubMed] [Google Scholar]
  67. Lacey J. H., Crisp A. H. Hunger, food intake and weight: the impact of clomipramine on a refeeding anorexia nervosa population. Postgrad Med J. 1980;56 (Suppl 1):79–85. [PubMed] [Google Scholar]
  68. Leibowitz S. F. Brain monoamines and peptides: role in the control of eating behavior. Fed Proc. 1986 Apr;45(5):1396–1403. [PubMed] [Google Scholar]
  69. Lesem M. D., George D. T., Kaye W. H., Goldstein D. S., Jimerson D. C. State-related changes in norepinephrine regulation in anorexia nervosa. Biol Psychiatry. 1989 Feb 15;25(4):509–512. doi: 10.1016/0006-3223(89)90208-4. [DOI] [PubMed] [Google Scholar]
  70. Levitan R. D., Kaplan A. S., Joffe R. T., Levitt A. J., Brown G. M. Hormonal and subjective responses to intravenous meta-chlorophenylpiperazine in bulimia nervosa. Arch Gen Psychiatry. 1997 Jun;54(6):521–527. doi: 10.1001/archpsyc.1997.01830180027004. [DOI] [PubMed] [Google Scholar]
  71. Levy A. B., Dixon K. N., Stern S. L. How are depression and bulimia related? Am J Psychiatry. 1989 Feb;146(2):162–169. doi: 10.1176/ajp.146.2.162. [DOI] [PubMed] [Google Scholar]
  72. Marcus M. D., Wing R. R., Ewing L., Kern E., McDermott M., Gooding W. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. Am J Psychiatry. 1990 Jul;147(7):876–881. doi: 10.1176/ajp.147.7.876. [DOI] [PubMed] [Google Scholar]
  73. Marcus M. D., Wing R. R., Ewing L., Kern E., McDermott M., Gooding W. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. Am J Psychiatry. 1990 Jul;147(7):876–881. doi: 10.1176/ajp.147.7.876. [DOI] [PubMed] [Google Scholar]
  74. Mayer L. E., Walsh B. T. The use of selective serotonin reuptake inhibitors in eating disorders. J Clin Psychiatry. 1998;59 (Suppl 15):28–34. [PubMed] [Google Scholar]
  75. Menkes D. B. Buspirone augmentation of sertraline. Br J Psychiatry. 1995 Jun;166(6):823–824. doi: 10.1192/s0007125000075292. [DOI] [PubMed] [Google Scholar]
  76. Mitchell J. E., Groat R. A placebo-controlled, double-blind trial of amitriptyline in bulimia. J Clin Psychopharmacol. 1984 Aug;4(4):186–193. [PubMed] [Google Scholar]
  77. Mitchell J. E., Pyle R. L., Eckert E. D., Hatsukami D., Pomeroy C., Zimmerman R. A comparison study of antidepressants and structured intensive group psychotherapy in the treatment of bulimia nervosa. Arch Gen Psychiatry. 1990 Feb;47(2):149–157. doi: 10.1001/archpsyc.1990.01810140049008. [DOI] [PubMed] [Google Scholar]
  78. Mitchell J. E., Raymond N., Specker S. A review of the controlled trials of pharmacotherapy and psychotherapy in the treatment of bulimia nervosa. Int J Eat Disord. 1993 Nov;14(3):229–247. doi: 10.1002/1098-108x(199311)14:3<229::aid-eat2260140302>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  79. Neumeister A., Winkler A., Wöber-Bingöl C. Addition of naltrexone to fluoxetine in the treatment of binge eating disorder. Am J Psychiatry. 1999 May;156(5):797–797. doi: 10.1176/ajp.156.5.797. [DOI] [PubMed] [Google Scholar]
  80. Pirke K. M., Broocks A., Wilckens T., Marquard R., Schweiger U. Starvation-induced hyperactivity in the rat: the role of endocrine and neurotransmitter changes. Neurosci Biobehav Rev. 1993 Fall;17(3):287–294. doi: 10.1016/s0149-7634(05)80012-0. [DOI] [PubMed] [Google Scholar]
  81. Pirke K. M. Central and peripheral noradrenalin regulation in eating disorders. Psychiatry Res. 1996 Apr 16;62(1):43–49. doi: 10.1016/0165-1781(96)02982-4. [DOI] [PubMed] [Google Scholar]
  82. Pope H. G., Jr, Hudson J. I., Jonas J. M. Antidepressant treatment of bulimia: preliminary experience and practical recommendations. J Clin Psychopharmacol. 1983 Oct;3(5):274–281. [PubMed] [Google Scholar]
  83. Pyle R. L., Mitchell J. E., Eckert E. D., Hatsukami D., Pomeroy C., Zimmerman R. Maintenance treatment and 6-month outcome for bulimic patients who respond to initial treatment. Am J Psychiatry. 1990 Jul;147(7):871–875. doi: 10.1176/ajp.147.7.871. [DOI] [PubMed] [Google Scholar]
  84. Robert J. M., Lydiard R. B. Sertraline in the treatment of bulimia nervosa. Am J Psychiatry. 1993 Nov;150(11):1753–1753. doi: 10.1176/ajp.150.11.1753b. [DOI] [PubMed] [Google Scholar]
  85. Russell G. F., Szmukler G. I., Dare C., Eisler I. An evaluation of family therapy in anorexia nervosa and bulimia nervosa. Arch Gen Psychiatry. 1987 Dec;44(12):1047–1056. doi: 10.1001/archpsyc.1987.01800240021004. [DOI] [PubMed] [Google Scholar]
  86. Scheen A. J., Lefébvre P. J. Pharmacological treatment of obesity: present status. Int J Obes Relat Metab Disord. 1999 Feb;23 (Suppl 1):47–53. doi: 10.1038/sj.ijo.0800795. [DOI] [PubMed] [Google Scholar]
  87. Smith D. E., Marcus M. D., Lewis C. E., Fitzgibbon M., Schreiner P. Prevalence of binge eating disorder, obesity, and depression in a biracial cohort of young adults. Ann Behav Med. 1998 Summer;20(3):227–232. doi: 10.1007/BF02884965. [DOI] [PubMed] [Google Scholar]
  88. Specker S., de Zwaan M., Raymond N., Mitchell J. Psychopathology in subgroups of obese women with and without binge eating disorder. Compr Psychiatry. 1994 May-Jun;35(3):185–190. doi: 10.1016/0010-440x(94)90190-2. [DOI] [PubMed] [Google Scholar]
  89. Stunkard A., Berkowitz R., Tanrikut C., Reiss E., Young L. d-fenfluramine treatment of binge eating disorder. Am J Psychiatry. 1996 Nov;153(11):1455–1459. doi: 10.1176/ajp.153.11.1455. [DOI] [PubMed] [Google Scholar]
  90. Tachibana N., Sugita Y., Teshima Y., Hishikawa Y. A case of anorexia nervosa associated with epileptic seizures showing favorable responses to sodium valproate and clonazepam. Jpn J Psychiatry Neurol. 1989 Mar;43(1):77–84. doi: 10.1111/j.1440-1819.1989.tb02554.x. [DOI] [PubMed] [Google Scholar]
  91. Toner B. B., Garfinkel P. E., Garner D. M. Long-term follow-up of anorexia nervosa. Psychosom Med. 1986 Sep-Oct;48(7):520–529. doi: 10.1097/00006842-198609000-00007. [DOI] [PubMed] [Google Scholar]
  92. Treasure J., Todd G., Brolly M., Tiller J., Nehmed A., Denman F. A pilot study of a randomised trial of cognitive analytical therapy vs educational behavioral therapy for adult anorexia nervosa. Behav Res Ther. 1995 May;33(4):363–367. doi: 10.1016/0005-7967(94)00070-z. [DOI] [PubMed] [Google Scholar]
  93. Vandereycken W. Neuroleptics in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled study with sulpiride. Br J Psychiatry. 1984 Mar;144:288–292. doi: 10.1192/bjp.144.3.288. [DOI] [PubMed] [Google Scholar]
  94. Vandereycken W., Pierloot R. Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled cross-over study. Acta Psychiatr Scand. 1982 Dec;66(6):445–450. doi: 10.1111/j.1600-0447.1982.tb04501.x. [DOI] [PubMed] [Google Scholar]
  95. Wadden T. A., Stunkard A. J. Social and psychological consequences of obesity. Ann Intern Med. 1985 Dec;103(6 ):1062–1067. doi: 10.7326/0003-4819-103-6-1062. [DOI] [PubMed] [Google Scholar]
  96. Waller D. A., Sheinberg A. l., Gullion C., Moeller F. G., Cannon D. S., Petty F., Hardy B. W., Orsulak P., Rush A. J. Impulsivity and neuroendocrine response to buspirone in bulimia nervosa. Biol Psychiatry. 1996 Mar 1;39(5):371–374. doi: 10.1016/0006-3223(95)00524-2. [DOI] [PubMed] [Google Scholar]
  97. Walsh B. T., Gladis M., Roose S. P., Stewart J. W., Stetner F., Glassman A. H. Phenelzine vs placebo in 50 patients with bulimia. Arch Gen Psychiatry. 1988 May;45(5):471–475. doi: 10.1001/archpsyc.1988.01800290091011. [DOI] [PubMed] [Google Scholar]
  98. Walsh B. T. Psychopharmacologic treatment of bulimia nervosa. J Clin Psychiatry. 1991 Oct;52 (Suppl):34–38. [PubMed] [Google Scholar]
  99. Walsh B. T., Wilson G. T., Loeb K. L., Devlin M. J., Pike K. M., Roose S. P., Fleiss J., Waternaux C. Medication and psychotherapy in the treatment of bulimia nervosa. Am J Psychiatry. 1997 Apr;154(4):523–531. doi: 10.1176/ajp.154.4.523. [DOI] [PubMed] [Google Scholar]
  100. Weisler R. H., Johnston J. A., Lineberry C. G., Samara B., Branconnier R. J., Billow A. A. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol. 1994 Jun;14(3):170–179. [PubMed] [Google Scholar]
  101. Weltzin T. E., Fernstrom J. D., McConaha C., Kaye W. H. Acute tryptophan depletion in bulimia: effects on large neutral amino acids. Biol Psychiatry. 1994 Mar 15;35(6):388–397. doi: 10.1016/0006-3223(94)90005-1. [DOI] [PubMed] [Google Scholar]
  102. Young C. R., Mazure C. M. Fulminant hepatic failure from acetaminophen in an anorexic patient treated with carbamazepine. J Clin Psychiatry. 1998 Nov;59(11):622–622. doi: 10.4088/jcp.v59n1109e. [DOI] [PubMed] [Google Scholar]
  103. Zarrindast M. R., Hosseini-Nia T. Anorectic and behavioural effects of bupropion. Gen Pharmacol. 1988;19(2):201–204. doi: 10.1016/0306-3623(88)90061-4. [DOI] [PubMed] [Google Scholar]
  104. de Zwaan M., Mitchell J. E., Raymond N. C., Spitzer R. L. Binge eating disorder: clinical features and treatment of a new diagnosis. Harv Rev Psychiatry. 1994 Mar-Apr;1(6):310–325. doi: 10.3109/10673229409017098. [DOI] [PubMed] [Google Scholar]
  105. de Zwaan M., Nutzinger D. O., Schoenbeck G. Binge eating in overweight women. Compr Psychiatry. 1992 Jul-Aug;33(4):256–261. doi: 10.1016/0010-440x(92)90050-z. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Psychiatry and Neuroscience are provided here courtesy of Canadian Medical Association

RESOURCES